Braidwell LP Buys Shares of 72,083 Trevi Therapeutics, Inc. $TRVI

Key Points

• Braidwell LP acquired a new stake in Trevi Therapeutics by purchasing 72,083 shares valued at approximately $453,000 in the first quarter.
• The company's stock recently traded at $7.26, with a market cap of $884.10 million and a PE ratio of -17.29.
• Analysts have mixed ratings for Trevi Therapeutics, with two giving it a Strong Buy rating and Oppenheimer maintaining an "outperform" rating despite recent price target adjustments.

Braidwell LP bought a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 72,083 shares of the company's stock, valued at approximately $453,000. Braidwell LP owned about 0.07% of Trevi Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in Trevi Therapeutics during the 4th quarter worth $49,000. Squarepoint Ops LLC purchased a new position in Trevi Therapeutics during the 4th quarter worth $58,000. Two Sigma Advisers LP purchased a new position in Trevi Therapeutics during the 4th quarter worth $66,000. Cantor Fitzgerald L. P. purchased a new position in Trevi Therapeutics during the 4th quarter worth $82,000. Finally, ProShare Advisors LLC grew its stake in Trevi Therapeutics by 86.4% during the 4th quarter. ProShare Advisors LLC now owns 20,685 shares of the company's stock worth $85,000 after buying an additional 9,589 shares during the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Stock Performance

Shares of TRVI traded down $0.22 during trading hours on Friday, hitting $7.01. The stock had a trading volume of 1,613,444 shares, compared to its average volume of 1,942,515. The firm has a market capitalization of $853.68 million, a price-to-earnings ratio of -16.69 and a beta of 0.71. The firm has a 50-day moving average price of $7.07 and a 200 day moving average price of $6.37. Trevi Therapeutics, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $8.78.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Wall Street Zen downgraded Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. D. Boral Capital reiterated a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Cantor Fitzgerald assumed coverage on Trevi Therapeutics in a research note on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price target on the stock. HC Wainwright assumed coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They set a "buy" rating and a $21.00 price target on the stock. Finally, Needham & Company LLC dropped their price target on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to data from MarketBeat.com, Trevi Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $20.11.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.